Search

Your search keyword '"Rogado J"' showing total 132 results
Start Over Author "Rogado J" Search Limiters Full Text
132 results on '"Rogado J"'

1. COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases

Author

Martin, P., Tsourti, Z., Ribeiro, J., Castelo-Branco, L., de Azambuja, E., Gennatas, S., Rogado, J., Sekacheva, M., Šušnjar, S., Viñal, D., Lee, R., Khallaf, S., Dimopoulou, G., Pradervand, S., Whisenant, J., Choueiri, T.K., Arnold, D., Harrington, K., Punie, K., Oliveira, J., Michielin, O., Dafni, U., Peters, S., Pentheroudakis, G., and Romano, E.

Published
2023
Full Text
View/download PDF

2. COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)

Author

Castelo-Branco, L., Tsourti, Z., Gennatas, S., Rogado, J., Sekacheva, M., Viñal, D., Lee, R., Croitoru, A., Vitorino, M., Khallaf, S., Šušnjar, S., Soewoto, W., Cardeña, A., Djerouni, M., Rossi, M., Alonso-Gordoa, T., Ngelangel, C., Whisenant, J.G., Choueiri, T.K., Dimopoulou, G., Pradervand, S., Arnold, D., Harrington, K., Michielin, O., Dafni, U., Pentheroudakis, G., Peters, S., and Romano, E.

Published
2022
Full Text
View/download PDF

3. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

Author

Trujillo‐Santos, Javier, Farge‐Bancel, Dominique, Pedrajas, José María, Gómez‐Cuervo, Covadonga, Ballaz, Aitor, Braester, Andrei, Mahé, Isabelle, Villalobos, Aurora, Porras, José Antonio, Monreal, Manuel, Adarraga, MD, Aibar, J, Aibar, MA, Amado, C, Arcelus, JI, Asuero, A, Barba, R, Barbagelata, C, Barrón, M, Barrón‐Andrés, B, Blanco‐Molina, A, Botella, E, Camon, AM, Casado, I, Castro, J, Castro, M, Chasco, L, Criado, J, de Ancos, C, del Toro, J, Demelo‐Rodríguez, P, Díaz‐Brasero, AM, Díaz‐Peromingo, JA, Di Campli, MV, Dubois‐Silva, A, Escribano, JC, Espósito, F, Falgá, C, Farfán‐Sedano, AI, Fernández‐Capitán, C, Fernández‐Reyes, JL, Fidalgo, MA, Flores, K, Font, C, Font, L, Francisco, I, Gabara, C, Galeano‐Valle, F, García, MA, García‐Bragado, F, García de Herreros, M, García de la Garza, R, García‐Díaz, C, García‐Hernáez, R, García‐Raso, A, Gil‐Díaz, A, Giménez‐Suau, M, Grau, E, Guirado, L, Gutiérrez, J, Hernández‐Blasco, L, Hernando, E, Jara‐Palomares, L, Jaras, MJ, Jiménez, D, Jiménez, R, Jiménez‐Alfaro, C, Joya, MD, Lainez‐Justo, S, Latorre, A, Lima, J, Llamas, P, Lobo, JL, López‐Jiménez, L, López‐Miguel, P, López‐Núñez, JJ, López‐Reyes, R, López‐Sáez, JB, Lorenzo, A, Madridano, O, Maestre, A, Marchena, PJ, Martín‐Martos, F, Martínez‐Urbistondo, D, Mella, C, Mercado, MI, Moisés, J, Morales, MV, Muñoz‐Blanco, A, Muñoz‐Rivas, N, Navas, MS, Nieto, JA, Nofuentes‐Pérez, E, Núñez‐Fernández, MJ, Obispo, B, Olid, M, Olivares, MC, Orcastegui, JL, Osorio, J, Otalora, S, Otero, R, Paredes, D, Parra, P, Pellejero, G, Portillo, J, Rivera‐Civico, F, Rodríguez‐Chiaradía, DA, Rodríguez‐Matute, C, Rogado, J, Rosa, V, Ruiz‐Artacho, P, Ruiz‐Giménez, N, Ruiz‐Ruiz, J, Ruiz‐Sada, P, Salgueiro, G, Sánchez‐Martínez, R, Sánchez‐Muñoz‐Torrero, JF, Sancho, T, Soler, S, Suárez‐Rodríguez, B, Suriñach, JM, Tirado, R, Torres, MI, Tolosa, C, Uresandi, F, Valero, B, Valle, R, Varona, JF, Vidal, G, Villares, P, Zamora, C, Engelen, M, Vanassche, T, Verhamme, P, Hirmerova, J, Malý, R, Ait Abdallah, N, Bertoletti, L, Bura‐Riviere, A, Catella, J, Couturaud, F, Crichi, B, Debourdeau, P, Espitia, O, Falvo, N, Helfer, H, Lacut, K, Le Mao, R, Moustafa, F, Poenou, G, Quere, I, Schellong, S, Brenner, B, Tzoran, I, Nikandish, R, Bilora, F, Brandolin, B, Ciammaichella, M, Di Micco, P, Imbalzano, E, Maida, R, Pace, F, Pesavento, R, Prandoni, P, Quintavalla, R, Rocci, A, Siniscalchi, C, Tufano, A, Visonà, A, Zalunardo, B, Birzulis, J, Skride, A, Zaicenko, A, Fonseca, S, Martins, F, Meireles, J, Bosevski, M, Bounameaux, H, Mazzolai, L, Ochoa‐Chaar, CI, Weinberg, I, and Bui, HM

Published
2022
Full Text
View/download PDF

4. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)

Author

Jiménez-Labaig, P., Pacheco-Barcia, V., Cebrià, A., Gálvez, F., Obispo, B., Páez, D., Quílez, A., Quintanar, T., Ramchandani, A., Remon, J., Rogado, J., Sánchez, D.A., Sánchez-Cánovas, M., Sanz-García, E., Sesma, A., Tarazona, N., Cotés, A., González, E., Bosch-Barrera, J., Fernández, A., Felip, E., Vera, R., Rodríguez-Lescure, Á., and Élez, E.

Published
2021
Full Text
View/download PDF

5. Comparative clinical prognosis of massive and non‐massive pulmonary embolism: A registry‐based cohort study

Author

Blondon, Marc, Jimenez, David, Robert‐Ebadi, Helia, Del Toro, Jorge, Lopez‐Jimenez, Luciano, Falga, Conxita, Skride, Andris, Font, Llorenç, Vazquez, Fernando Javier, Bounameaux, Henri, Monreal, Manuel, Prandoni, Paolo, Brenner, Benjamin, Farge‐Bancel, Dominique, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Schellong, Sebastian, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Malý, Radovan, Verhamme, Peter, Caprini, Joseph A, My Bui, Hanh, Adarraga, MD, Agud, M, Aibar, J, Aibar, MA, Alfonso, J, Amado, C, Arcelus, JI, Baeza, C, Ballaz, A, Barba, R, Barbagelata, C, Barrón, M, Barrón‐Andrés, B, Blanco‐Molina, A, Botella, E, Camon, AM, Castro, J, Caudevilla, MA, Cerdà, P, Chasco, L, Criado, J, de Ancos, C, de Miguel, J, Demelo‐Rodríguez, P, Díaz‐Peromingo, JA, Díez‐Sierra, J, Díaz‐Simón, R, Domínguez, IM, Encabo, M, Escribano, JC, Falgá, C, Farfán, AI, Fernández‐Capitán, C, Fernández‐Reyes, JL, Fidalgo, MA, Flores, K, Font, C, Francisco, I, Gabara, C, Galeano‐Valle, F, García, MA, García‐Bragado, F, García‐Mullor, MM, Gavín‐Blanco, O, Gavín‐Sebastián, O, Gil‐Díaz, A, Gómez‐Cuervo, C, González‐Martínez, J, Grau, E, Guirado, L, Gutiérrez, J, Hernández‐Blasco, L, Jara‐Palomares, L, Jaras, MJ, Jiménez, D, Joya, MD, Jou, I, Lacruz, B, Lecumberri, R, Lima, J, Lobo, JL, López‐Brull, H, López‐Jiménez, L, López‐Miguel, P, López‐Núñez, JJ, López‐Reyes, R, López‐Sáez, JB, Lorente, MA, Lorenzo, A, Loring, M, Madridano, O, Maestre, A, Marchena, PJ, Martín del Pozo, M, Martín‐Martos, F, Martínez‐Baquerizo, C, Mella, C, Mellado, M, Mercado, MI, Moisés, J, Morales, MV, Muñoz‐Blanco, A, Muñoz‐Guglielmetti, D, Muñoz‐Rivas, N, Nart, E, Nieto, JA, Núñez, MJ, Olivares, MC, Ortega‐Michel, C, Ortega‐Recio, MD, Osorio, J, Otalora, S, Otero, R, Parra, P, Parra, V, Pedrajas, JM, Pellejero, G, Pérez‐Jacoiste, A, Peris, ML, Pesántez, D, Porras, JA, Portillo, J, Reig, L, Riera‐Mestre, A, Rivas, A, Rodríguez‐Cobo, A, Rodríguez‐Matute, C, Rogado, J, Rosa, V, Rubio, CM, Ruiz‐Artacho, P, Ruiz‐Giménez, N, Ruiz‐Ruiz, J, Ruiz‐Sada, P, Sahuquillo, JC, Salgueiro, G, Sampériz, A, Sánchez‐Muñoz‐Torrero, JF, Sancho, T, Sigüenza, P, Sirisi, M, Soler, S, Suárez, S, Suriñach, JM, Tiberio, G, Torres, MI, Tolosa, C, Trujillo‐Santos, J, Uresandi, F, Usandizaga, E, Valle, R, Vela, JR, Vidal, G, Vilar, C, Villares, P, Zamora, C, Gutiérrez, P, Vázquez, FJ, Vanassche, T, Vandenbriele, C, Verhamme, P, Hirmerova, J, Malý, R, Salgado, E, Benzidia, I, Bertoletti, L, Bura‐Riviere, A, Crichi, B, Debourdeau, P, Espitia, O, Farge‐Bancel, D, Helfer, H, Mahé, I, Moustafa, F, Poenou, G, Schellong, S, Braester, A, Brenner, B, Tzoran, I, Amitrano, M, Bilora, F, Bortoluzzi, C, Brandolin, B, Ciammaichella, M, Colaizzo, D, Dentali, F, Di Micco, P, Giammarino, E, Grandone, E, Mangiacapra, S, Mastroiacovo, D, Maida, R, Mumoli, N, Pace, F, Pesavento, R, Pomero, F, Prandoni, P, Quintavalla, R, Rocci, A, Siniscalchi, C, Tufano, A, Visonà, A, Vo Hong, N, Zalunardo, B, Kalejs, RV, Maķe, K, Ferreira, M, Fonseca, S, Martins, F, Meireles, J, Bosevski, M, Zdraveska, M, Mazzolai, L, Caprini, JA, Tafur, AJ, Weinberg, I, Wilkins, H, and Bui, HM

Published
2021
Full Text
View/download PDF

6. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry

Author

Adarraga, M.D., Agud, M., Aibar, J., Aibar, M.A., Amado, C., Arcelus, J.I., Baeza, C., Ballaz, A., Barba, R., Barbagelata, C., Barrón, M., Barrón-Andrés, B., Bernal, M., Blanco-Molina, A., Botella, E., Camon, A.M., Cañas, I., Casado, I., Castro, J., Chasco, L., Criado, J., de Ancos, C., de Miguel, J., del Toro, J., Demelo-Rodríguez, P., Díaz-Peromingo, J.A., Di Campli, M.V., Díez-Sierra, J., Domínguez, I.M., Encabo, M., Escribano, J.C., Falgá, C., Farfán-Sedano, A.I., Fernández de Roitegui, K., Fernández-Capitán, C., Fernández-Reyes, J.L., Fidalgo, M.A., Flores, K., Font, C., Font, L., Francisco, I., Furest, I., Gabara, C., Galeano-Valle, F., García, M.A., García-Bragado, F., García de Herreros, M., García-Hernáez, R., García-Mullor, M.M., García-Raso, A., Gavín-Sebastián, O., Gil-Díaz, A., Gómez-Cuervo, C., González-Martínez, J., Grau, E., Giménez-Suau, M., Guirado, L., Gutiérrez, J., Hernández-Blasco, L., Hernando, E., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Joya, M.D., Jou, I., Lima, J., Llamas, P., Lobo, J.L., López-Jiménez, L., López-Miguel, P., López-Núñez, J.J., López-Reyes, R., López-Sáez, J.B., Lorenzo, A., Loring, M., Madridano, O., Maestre, A., Marchena, P.J., Martín del Pozo, M., Martín-Martos, F., Mella, C., Mellado, M., Mercado, M.I., Moisés, J., Monreal, M., Morales, M.V., Muñoz-Blanco, A., Muñoz-Guglielmetti, D., Muñoz-Rivas, N., Navas, M.S., Nieto, J.A., Núñez-Ares, A., Núñez-Fernández, M.J., Obispo, B., Olid, M., Olivares, M.C., Orcastegui, J.L., Ortega-Recio, M.D., Osorio, J., Otalora, S., Otero, R., Parra, P., Parra, V., Pedrajas, J.M., Peinado, A., Pellejero, G., Pérez-Jacoiste, A., Porras, J.A., Portillo, J., Riera-Mestre, A., Rivas, A., Rivera, F., Rodríguez-Chiaradía, D.A., Rodríguez-Cobo, A., Rodríguez-Matute, C., Rogado, J., Rojo, R., Rosa, V., Ruiz-Artacho, P., Ruiz-Giménez, N., Ruiz-Ruiz, J., Ruiz-Sada, P., Sahuquillo, J.C., Salgueiro, G., Sampériz, A., Sánchez-Martínez, R., Sánchez-Muñoz-Torrero, J.F., Sancho, T., Soler, S., Suriñach, J.M., Tirado, R., Torres, M.I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Vela, J.R., Vidal, G., Villares, P., Zamora, C., Gutiérrez, P., Vázquez, F.J., Engelen, M., Vanassche, T., Vehamme, P., Hirmerova, J., Malý, R., Ait Abdallah, N., Bertoletti, L., Bura-Riviere, A., Crichi, B., Debourdeau, P., Espitia, O., Farge-Bancel, D., Helfer, H., Mahé, I., Moustafa, F., Poenou, G., Schellong, S., Braester, A., Brenner, B., Tzoran, I., Bilora, F., Brandolin, B., Bucherini, E., Ciammaichella, M., Colaizzo, D., Di Micco, P., Grandone, E., Imbalzano, E., Maida, R., Mastroiacovo, D., Pace, F., Pesavento, R., Prandoni, P., Quintavalla, R., Rocci, A., Siniscalchi, C., Tufano, A., Visonà, A., Zalunardo, B., Skride, A., Strautmane, S., Zaicenko, A., Ferreira, M., Fonseca, S., Martins, F., Meireles, J., Bosevski, M., Bounameaux, H., Mazzolai, L., Caprini, J.A., Tafur, A.J., Weinberg, I., Wilkins, H., Bui, H.M., Núñez Fernández, Manuel J., Martínez Reglero, Cristina, Nieto Rodríguez, José Antonio, Chouza Piñeiro, Ana, Barcia Sixto, Laura, Maestre Peiró, Ana, Trujillo Santos, Javier, Visonà, Adriana, Fernández-Reyes, José Luis, and Monreal Bosch, Manuel

Published
2020
Full Text
View/download PDF

7. P1.22-16 ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments

Author

Robado de Lope, L., primary, Serna-Blasco, R., additional, Mediavilla, P., additional, Sanz-Moreno, S., additional, Rodríguez-Festa, A., additional, Gallego-Gil, P., additional, Flores, C., additional, Calvo, V., additional, Collazo-Lorduy, A., additional, Blanco, M., additional, Peña Cabia, S., additional, Diz Tain, P., additional, Garrido Onecha, M.L., additional, Sánchez-Hernández, A., additional, Sequero López, S., additional, Rogado, J., additional, Coves Sarto, J., additional, López Martín, A., additional, Mielgo, X., additional, Vázquez Estévez, S., additional, González-Rumayor, V., additional, Romero, A., additional, and Provencio, M., additional

Published
2023
Full Text
View/download PDF

8. 237P Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: A joint analysis of OnCovid and ESMO-CoCARE registries

Author

Cortellini, A., primary, Dettorre, G., additional, Dafni, U., additional, Aguilar Company, J., additional, Castelo-Branco, L., additional, Lambertini, M., additional, Gennatas, S., additional, Rogado, J., additional, Vinal Lozano, D., additional, Harrington, K.J., additional, Tsourti, Z., additional, Michielin, O.A., additional, Pommeret, F., additional, Brunet Vidal, J.M., additional, Tabernero, J., additional, Pentheroudakis, G., additional, Gennari, A., additional, Peters, S., additional, Romano, E., additional, and Pinato, D.J., additional

Published
2022
Full Text
View/download PDF

10. LBA70 COVID-19 in cancer patients: Update from the joint analysis of ESMO-CoCARE, BSMO, PSMO international databases

Author

Romano, E., primary, Castelo-Branco, L., additional, Tsourti, Z., additional, de Azambuja, E., additional, Gennatas, S., additional, Oliveira, J., additional, Rogado, J., additional, Sekacheva, M., additional, Susnjar, S., additional, Lozano, D. Vinal, additional, Lee, R., additional, Khallaf, S.M., additional, Dimopoulou, G., additional, Pradervand, S., additional, Arnold, D., additional, Harrington, K.J., additional, Michielin, O.A., additional, Dafni, U., additional, Pentheroudakis, G., additional, and Peters, S., additional

Published
2022
Full Text
View/download PDF

11. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

Author

Whisenant, J. G., Baena, J., Cortellini, A., Huang, L. C., Lo Russo, G., Porcu, L., Wong, S. K., Bestvina, C. M., Hellmann, M. D., Roca, E., Rizvi, H., Monnet, I., Boudjemaa, A., Rogado, J., Pasello, G., Leighl, N. B., Arrieta, O., Aujayeb, A., Batra, U., Azzam, A. Y., Unk, M., Azab, M. A., Zhumagaliyeva, A. N., Gomez-Martin, C., Blaquier, J. B., Geraedts, E., Mountzios, G., Serrano-Montero, G., Reinmuth, N., Coate, L., Marmarelis, M., Presley, C. J., Hirsch, F. R., Garrido, P., Khan, H., Baggi, A., Mascaux, C., Halmos, B., Ceresoli, G. L., Fidler, M. J., Scotti, V., Métivier, A. C., Falchero, L., Felip, E., Genova, C., Mazieres, J., Tapan, U., Brahmer, J., Dingemans, A. M., Peters, S., Whisenant, J. G., Baena, J., Cortellini, A., Huang, L. C., Lo Russo, G., Porcu, L., Wong, S. K., Bestvina, C. M., Hellmann, M. D., Roca, E., Rizvi, H., Monnet, I., Boudjemaa, A., Rogado, J., Pasello, G., Leighl, N. B., Arrieta, O., Aujayeb, A., Batra, U., Azzam, A. Y., Unk, M., Azab, M. A., Zhumagaliyeva, A. N., Gomez-Martin, C., Blaquier, J. B., Geraedts, E., Mountzios, G., Serrano-Montero, G., Reinmuth, N., Coate, L., Marmarelis, M., Presley, C. J., Hirsch, F. R., Garrido, P., Khan, H., Baggi, A., Mascaux, C., Halmos, B., Ceresoli, G. L., Fidler, M. J., Scotti, V., Métivier, A. C., Falchero, L., Felip, E., Genova, C., Mazieres, J., Tapan, U., Brahmer, J., Dingemans, A. M., and Peters, S.

Abstract

Introduction: Patients with thoracic malignancies are at increased risk for mortality from coronavirus disease 2019 (COVID-19), and a large number of intertwined prognostic variables have been identified so far. Methods: Capitalizing data from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry, a global study created with the aim of describing the impact of COVID-19 in patients with thoracic malignancies, we used a clustering approach, a fast-backward step-down selection procedure, and a tree-based model to screen and optimize a broad panel of demographics and clinical COVID-19 and cancer characteristics. Results: As of April 15, 2021, a total of 1491 consecutive eligible patients from 18 countries were included in the analysis. With a mean observation period of 42 days, 361 events were reported with an all-cause case fatality rate of 24.2%. The clustering procedure screened 73 covariates in 13 clusters. A further multivariable logistic regression for the association between clusters and death was performed, resulting in five clusters significantly associated with the outcome. The fast-backward step-down selection procedure then identified the following seven major determinants of death: Eastern Cooperative Oncology Group—performance status (ECOG-PS) (OR = 2.47, 1.87–3.26), neutrophil count (OR = 2.46, 1.76–3.44), serum procalcitonin (OR = 2.37, 1.64–3.43), development of pneumonia (OR = 1.95, 1.48–2.58), C-reactive protein (OR = 1.90, 1.43–2.51), tumor stage at COVID-19 diagnosis (OR = 1.97, 1.46–2.66), and age (OR = 1.71, 1.29–2.26). The receiver operating characteristic analysis for death of the selected model confirmed its diagnostic ability (area under the receiver operating curve = 0.78, 95% confidence interval: 0.75–0.81). The nomogram was able to classify the COVID-19 mortality in an interval ranging from 8% to 90%, and the tree-based model recognized ECOG-PS, neutrophil count, and c-reactive protein as the major determinants of

Published
2022

12. Measurement properties of the Spanish version of the brief resilient coping scale (BRCS) in cancer patients

Author

Universitat Rovira i Virgili, Calderon, C; Lorenzo-Seva, U; Ferrando, PJ; Sorribes, E; Rodriguez-gonzalez, A; Obispo, BM; Mihic-Gongora, L; Corral, MJ; Rogado, J; Cruz-Castellanos, P; Jimenez-fonseca, P, Universitat Rovira i Virgili, and Calderon, C; Lorenzo-Seva, U; Ferrando, PJ; Sorribes, E; Rodriguez-gonzalez, A; Obispo, BM; Mihic-Gongora, L; Corral, MJ; Rogado, J; Cruz-Castellanos, P; Jimenez-fonseca, P

Abstract

Background/Objective: Resilience is the capacity to adaptively confront stress. The aim of this study was to evaluate the psychometric properties, convergent validity, and factorial invariance of the Spanish version of the Brief Resilient Coping Scale (BRCS). Method: Exploratory and confirmatory factor analyses based on a cross-validation were conducted to explore the scale's dimensionality and test for strong (scalar) measurement invariance across gender, age, tumor site, and survival, by fitting multiple-group confirmatory solutions. An extended structural equation model was used to assess external validity. Prospective, multicenter cohort study of 636 patients who completed the BRCS, Satisfaction with Life Scale (SWLS), and Spiritual well-being (FACIT-sp) scales. Results: The data supported a unidimensional structure. The BRCS is a very short, narrow bandwidth measure, with items demonstrating high discriminating power. A strong invariance solution demonstrated excellent fit across gender, age, tumor site, and survival. Scores derived from the unidimensional structure exhibited satisfactory degrees of reliability (v = .86) and determinacy (FDI = .94). BRCS revealed substantial associations with satisfaction with life and spirituality well-being (all p < .001), factors widely related to resilience, particularly in cancer patients. Conclusions: The Spanish version of the BRCS is a reliable, valid resilience measure in advanced cancer. (c) 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Published
2022

13. Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?

Author

Camporese, G., Simioni, P., Di Micco, P., Fernandez-Capitan, C., Rivas, A., Font, C., Sahuquillo, J. C., Villares, P., Prandoni, P., Monreal, M., Adarraga, M. D., Agud, M., Aibar, J., Aibar, M. A., Alfonso, J., Amado, C., Arcelus, J. I., Baeza, C., Ballaz, A., Barba, R., Barbagelata, C., Barron, M., Barron-Andres, B., Blanco-Molina, A., Camon, A. M., Castro, J., Caudevilla, M. A., Cerda, P., Chasco, L., Criado, J., de Ancos, C., de Miguel, J., del Toro, J., Demelo-Rodriguez, P., Diaz-Peromingo, J. A., Diez-Sierra, J., Dominguez, I. M., Encabo, M., Escribano, J. C., Falga, C., Farfan, A. I., Fernandez de Roitegui, K., Fernandez-Reyes, J. L., Fidalgo, M. A., Flores, K., Font, L., Francisco, I., Gabara, C., Galeano-Valle, F., Garcia, M. A., Garcia-Bragado, F., Garcia-Mullor, M. M., Gavin-Blanco, O., Gavin-Sebastian, O., Gil-Diaz, A., Gomez-Cuervo, C., Gonzalez-Martinez, J., Grau, E., Guirado, L., Gutierrez, J., Hernandez-Blasco, L., Jara-Palomares, L., Jaras, M. J., Jimenez, D., Joya, M. D., Jou, I., Lacruz, B., Lalueza, A., Lecumberri, R., Lima, J., Lobo, J. L., Lopez-Brull, H., Lopez-Jimenez, L., Lopez-Miguel, P., Lopez-Nunez, J. J., Lopez-Reyes, R., Lopez-Saez, J. B., Lorente, M. A., Lorenzo, A., Loring, M., Madridano, O., Maestre, A., Marchena, P. J., Martin del Pozo, M., Martin-Martos, F., Martinez-Baquerizo, C., Mella, C., Mellado, M., Mercado, M. I., Moises, J., Morales, M. V., Munoz-Blanco, A., Munoz-Guglielmetti, D., Munoz-Rivas, N., Nart, E., Nieto, J. A., Nunez, M. J., Olivares, M. C., Ortega-Recio, M. D., Osorio, J., Otalora, S., Otero, R., Paredes, D., Parra, P., Parra, V., Pedrajas, J. M., Pellejero, G., Peris, M. L., Pesantez, D., Porras, J. A., Portillo, J., Ramos, E., Reig, L., Riera-Mestre, A., Rodriguez-Cobo, A., Rodriguez-Matute, C., Rogado, J., Rosa, V., Rubio, C. M., Ruiz-Artacho, P., Ruiz-Gimenez, N., Ruiz-Ruiz, J., Ruiz-Sada, P., Salgueiro, G., Samperiz, A., Sanchez-Munoz-Torrero, J. F., Sancho, T., Siguenza, P., Sirisi, M., Soler, S., Suarez, S. Surinach J. M., Tiberio, G., Torres, M. I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Vela, J. R., Vidal, G., Vilar, C., Zamora, C., Gutierrez, P., Vazquez, F. J., Vanassche, T., Vandenbriele, C., Verhamme, P., Hirmerova, J., Maly, R., Salgado, E., Benzidia, I., Bertoletti, L., Bura-Riviere, A., Crichi, B., Debourdeau, P., Espitia, O., Farge-Bancel, D., Helfer, H., Mahe, I., Moustafa, F., Poenou, G., Schellong, S., Braester, A., Brenner, B., Tzoran, I., Amitrano, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Ciammaichella, M., Colaizzo, D., Dentali, F., Giammarino, E., Grandone, E., Mangiacapra, S., Mastroiacovo, D., Maida, R., Mumoli, N., Pace, F., Pesavento, R., Pomero, F., Quintavalla, R., Rocci, A., Siniscalchi, C., Tufano, A., Visona, A., Vo Hong, N., Zalunardo, B., Make, K., Meilanden, K., Skride, A., Ferreira, M., Fonseca, S., Martins, F., Meireles, J., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Caprini, J. A., Tafur, A. J., Weinberg, I., Wilkins, H., Bui, H. M., and UAM. Departamento de Medicina

Subjects
Male, medicine.medical_specialty, Time Factors, Dose, Medicina, Pyridines, Hemorrhage, General Biochemistry, Genetics and Molecular Biology, Article, chemistry.chemical_compound, Edoxaban, Recurrence, Internal medicine, medicine, Humans, Prospective Studies, Registries, General Pharmacology, Toxicology and Pharmaceutics, Long term therapy, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Drug Tapering, business.industry, lcsh:Public aspects of medicine, General Neuroscience, Mortality rate, Research, lcsh:RM1-950, Hazard ratio, Anticoagulants, lcsh:RA1-1270, General Medicine, Articles, Venous Thromboembolism, Middle Aged, Confidence interval, Thiazoles, lcsh:Therapeutics. Pharmacology, chemistry, Practice Guidelines as Topic, Dose reduction, Female, business, Venous thromboembolism, Follow-Up Studies
Abstract

Edoxaban is used for venous thromboembolism (VTE) treatment. Real-life data are lacking about its use in long-term therapy. We aimed to assess the efficacy and the safety of edoxaban for long-term VTE treatment in a real-life setting. Patients with VTE included in the Registro Informatizado Enfermedad TromboEmbólica (RIETE) registry, receiving edoxaban 60 or 30 mg daily were prospectively followed up to validate the benefit of using different dosages. The main outcome was the composite of VTE recurrences or major bleeding in patients with or without criteria for dose reduction. Multivariable analysis to identify predictors for the composite outcome was performed. From October 2015 to November 2019, 562 patients received edoxaban for long-term therapy. Most (94%) of the 416 patients not meeting criteria for dose reduction received 60 mg daily, and 92 patients meeting criteria (63%) received 30 mg daily. During treatment, two patients developed recurrent VTE, six had major bleeding and nine died (2 from fatal bleeding). Among patients not meeting criteria for dose reduction, those receiving 30 mg daily had a higher rate of the composite event (hazard ratio (HR) 8.37; 95% confidence interval (CI) 1.12–42.4) and a significant higher mortality rate (HR 31.1; 95% CI 4.63–262) than those receiving 60 mg. Among patients meeting criteria for dose reduction, those receiving 60 mg daily had no events, and a nonsignificantly higher mortality rate (HR 5.04; 95% CI 0.54–133) than those receiving 30 mg daily. In conclusion, edoxaban seems to be effective and safe for long-term VTE treatment in real life. Criteria for dose reduction should be reformulated., No funding was received for this work

Published
2020

14. COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)

Author

Castelo-Branco, L. Tsourti, Z. Gennatas, S. Rogado, J. Sekacheva, M. Viñal, D. Lee, R. Croitoru, A. Vitorino, M. Khallaf, S. Šušnjar, S. Soewoto, W. Cardeña, A. Djerouni, M. Rossi, M. Alonso-Gordoa, T. Ngelangel, C. Whisenant, J.G. Choueiri, T.K. Dimopoulou, G. Pradervand, S. Arnold, D. Harrington, K. Michielin, O. Dafni, U. Pentheroudakis, G. Peters, S. Romano, E.

Abstract

Background: ESMO COVID-19 and CAncer REgistry (ESMO-CoCARE) is an international collaborative registry-based, cohort study gathering real-world data from Europe, Asia/Oceania and Africa on the natural history, management and outcomes of patients with cancer infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Patients and methods: ESMO-CoCARE captures information on patients with solid/haematological malignancies, diagnosed with coronavirus disease 2019 (COVID-19). Data collected since June 2020 include demographics, comorbidities, laboratory measurements, cancer characteristics, COVID-19 clinical features, management and outcome. Parameters influencing COVID-19 severity/recovery were investigated as well as factors associated with overall survival (OS) upon SARS-CoV-2 infection. Results: This analysis includes 1626 patients from 20 countries (87% from 24 European, 7% from 5 North African, 6% from 8 Asian/Oceanian centres), with COVID-19 diagnosis from January 2020 to May 2021. Median age was 64 years, with 52% of female, 57% of cancer stage III/IV and 65% receiving active cancer treatment. Nearly 64% patients required hospitalization due to COVID-19 diagnosis, with 11% receiving intensive care. In multivariable analysis, male sex, older age, Eastern Cooperative Oncology Group (ECOG) performance status ≥2, body mass index (BMI)

Published
2022

15. Anxiety and depression in patients with advanced cancer during the COVID-19 pandemic

Author

Obispo-Portero B, Cruz-Castellanos P, Jimenez-Fonseca P, Rogado J, Hernandez R, Castillo-Trujillo O, Asensio-Martinez E, Gonzalez-Moya M, Carmona-Bayonas A, and Calderon C

Subjects
Depression, Advanced cancer, COVID-19, Hopelessness, Anxiety
Abstract

Objective Cancer patients are at increased risk for psychological difficulties and COVID-19. We sought to analyze anxiety and depression levels during the COVID-19 pandemic and the association between sociodemographic, clinical, and psychological factors in patients with advanced cancer. Methods A prospective, multicenter cohort of 401 consecutive patients with newly diagnosed, advanced cancer completed the Brief Symptom Inventory, Michel Uncertainty in Illness Scale, Herth Hope Index, and Cancer Worry Scale between February 2020 and May 2021. Linear regression analyses explored the effects of uncertainty, hopelessness, and cancer worry on anxiety and depression, adjusting for sociodemographic and clinical variables. Results The incidence of anxiety and depression was 36% and 35%, respectively. Emotional distress was greater among women, patients < 65 years of age, and those with an estimated survival of > 18 months. Linear regression analysis revealed that being female, preoccupation about cancer, and hopelessness were associated with increased levels of anxiety (p < 0.001) and depression (p < 0.001) and younger age was associated with a higher risk of anxiety. No differences in anxiety or depression levels were found in relation to marital status, children, educational level, cancer type, histology, stage, or type of treatment. Conclusions Patients with advanced cancer who initiated treatment during the pandemic experienced high levels of depression and anxiety. Early diagnosis and the development of intervention strategies are necessary, especially for specific patient subgroups, such as young women with long survival times.

Published
2022

16. 1494P Anxiety and depression during the COVID-19 pandemic in newly diagnosed advanced cancer patients

Author

Obispo, B., primary, Hernandez, R., additional, Cruz, P., additional, Fernandez Montes, A., additional, Gil Raga, M., additional, Garcia, O.A., additional, Rogado, J., additional, Asensio-Martinez, E., additional, Piera Molons, N., additional, Pacheco-Barcia, V., additional, López de Ceballos, M.H., additional, Cano, J.M., additional, Ostios Garcia, L., additional, Antoñanzas Basa, M., additional, Lorente, D., additional, Manzano Fernández, A., additional, Hernando Polo, S., additional, Gonzalez Moya, M., additional, Garcia, T., additional, and Calderon, C., additional

Published
2021
Full Text
View/download PDF

17. 1567MO COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE)

Author

Romano, E., primary, Gennatas, S., additional, Rogado, J., additional, Sekacheva, M., additional, Viñal, D., additional, Lee, R., additional, Croitoru, A-E., additional, Vitorino, M., additional, Khallaf, S.M., additional, Susnjar, S., additional, Widyanti, S., additional, Cardeña, A., additional, Djerouni, M., additional, Rossi, M., additional, Arnold, D., additional, Castelo-Branco, L., additional, Harrington, K.J., additional, Michielin, O.A., additional, Pentheroudakis, G., additional, and Peters, S., additional

Published
2021
Full Text
View/download PDF

18. 1287P Immune T-cell subpopulations from the peripheral blood of non-small cell lung cancer patients are associated with the efficacy of anti-PD-1 immunotherapy

Author

Rogado, J., primary, Pozo, F., additional, Troulè, K., additional, Sánchez-Torres, J.M., additional, Laorden, N. Romero, additional, Solís, R. Mondéjar, additional, Candil, O. Donnay, additional, García, A.I. Ballesteros, additional, Pacheco-Barcia, V., additional, Aspa, J., additional, Al-Shahrour, F., additional, Alfranca, A., additional, and Colomer, R., additional

Published
2021
Full Text
View/download PDF

21. P-168 Differences in coping strategies used by colorectal vs. non-colorectal cancer patients: Data from the Neoetic-SEOM study

Author

Pacheco-Barcia, V., primary, Hernandez Sangil, R., additional, Fernández Montes, A., additional, Cruz Castellanos, P., additional, Castillo Trujillo, A., additional, Rogado, J., additional, Antoñanzas, M., additional, Gil Raga, M., additional, Manzano, A., additional, Asensio, H., additional, Lorente, D., additional, Obispo, B., additional, Ostios, L., additional, López de Ceballos, M., additional, Valero Arbizu, M., additional, García Carrasco, M., additional, Maria Cano, J., additional, Piera, N., additional, Carmona-Bayonas, A., additional, García, T., additional, and Calderón, C., additional

Published
2021
Full Text
View/download PDF

24. Optimism and social support as contributing factors to spirituality in Cancer patients

Author

Ciria-Suarez L, Calderon C, Montes A, Antonanzas M, Hernandez R, Rogado J, Pacheo-Barcia V, Ansensio-Martinez E, Palacin-Lois M, and Jimenez-Fonseca P

Subjects
Social support, Optimism, Spirituality, Cancer
Abstract

Background/objective The impact a cancer diagnosis and its treatment are affected by psychosocial factors and how these factors interrelate among themselves. The objective of this study was to analyze the relationship between optimism and social support in spiritual wellbeing in cancer patients initiating chemotherapy. Methods A cross-sectional, multi-center (15 sites), prospective study was conducted with 912 cancer patients who had undergone curative surgery for a stage I-III cancer and were to receive adjuvant chemotherapy. They completed the Functional Assessment of Chronic Illness-Spiritual Well-being Scale (FACIT-Sp), Life Orientation Test-Revised (LOT-R), and the Multidimensional Scale of Perceived Social Support (MSPSS). Results Significant differences on spirituality scales (meaning/peace and faith) were detected depending on age ( 65), sex, marital status, employment, and cancer treatment. Married or partnered participants had significantly higher meaning/peace scores compared to their non-partnered counterparts (p = 0.001). Women, > 65 years, unemployed, and patients treated with chemotherapy and radiotherapy had significantly higher faith scores versus men

Published
2021

28. Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis

Author

Mestre-Gómez, B., Lorente-Ramos, R. M., Rogado, J., Franco-Moreno, A., Obispo, B., Salazar-Chiriboga, D., Saez-Vaquero, T., Torres-Macho, J., Abad-Motos, A., Cortina-Camarero, C., Such-Diaz, A., Ruiz-Velasco, E., Churruca-Sarasqueta, J., Muñoz-Rivas, N., Sierra-Hidalgo, F., Moya-Mateo, E., de Carranza-López, M., Herrera-Moroueco, M. A., Akasbi-Montalvo, M., Pardo-Guimerá, V., Medrano-Izquierdo, P., Mariscal-Gómez, E., Marín-Mori, K., Figueras-González, C., López-Lallave, S., Díaz-Díaz, D., Mauleón-Fernández, C., Martín-Navarro, J., Torres-Rubio, P., Matesanz, C., Moro-Alvarez, M. J., Bustamante-Fermosel, A., and Hernández-Rivas, J. S. A.

Subjects
Male, medicine.medical_specialty, Computed Tomography Angiography, medicine.drug_class, Low molecular weight heparin, 030204 cardiovascular system & hematology, Thrombophilia, Chemoprevention, Article, Fibrin Fibrinogen Degradation Products, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Pulmonary angiography, Electronic Health Records, Humans, Medicine, Cumulative incidence, 030212 general & internal medicine, Lung, Computed tomography angiography, Antithrombotic therapy, medicine.diagnostic_test, SARS-CoV-2, business.industry, Incidence, Incidence (epidemiology), Pulmonary embolism, COVID-19, Anticoagulants, Hematology, Middle Aged, medicine.disease, COVID-19 Drug Treatment, Computed tomography pulmonary angiography, Causality, Hospitalization, Spain, Hypercoagulable state, Female, business, Cardiology and Cardiovascular Medicine, Dyslipidemia
Abstract

Recent studies suggest that thrombotic complications are a common phenomenon in the novel SARS-CoV-2 infection. The main objective of our study is to assess cumulative incidence of pulmonary embolism (PE) in non critically ill COVID-19 patients and to identify its predicting factors associated to the diagnosis of pulmonary embolism. We retrospectevely reviewed 452 electronic medical records of patients admitted to Internal Medicine Department of a secondary hospital in Madrid during Covid 19 pandemic outbreak. We included 91 patients who underwent a multidetector Computed Tomography pulmonary angiography(CTPA) during conventional hospitalization. The cumulative incidence of PE was assessed ant the clinical, analytical and radiological characteristics were compared between patients with and without PE. PE incidence was 6.4% (29/452 patients). Most patients with a confirmed diagnosed with PE recieved low molecular weight heparin (LMWH): 79.3% (23/29). D-dimer peak was significatly elevated in PE vs non PE patients (14,480 vs 7230 mcg/dL, p = 0.03). In multivariate analysis of patients who underwent a CTPA we found that plasma D-dimer peak was an independen predictor of PE with a best cut off point of > 5000 µg/dl (OR 3.77; IC95% (1.18–12.16), p = 0.03). We found ninefold increased risk of PE patients not suffering from dyslipidemia (OR 9.06; IC95% (1.88–43.60). Predictive value of AUC for ROC is 75.5%. We found a high incidence of PE in non critically ill hospitalized COVID 19 patients despite standard thromboprophylaxis. An increase in D-dimer levels is an independent predictor for PE, with a best cut-off point of > 5000 µg/ dl.

Published
2020
Full Text
View/download PDF

29. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry

Author

Núñez Fernández, Manuel J., primary, Martínez Reglero, Cristina, additional, Nieto Rodríguez, José Antonio, additional, Chouza Piñeiro, Ana, additional, Barcia Sixto, Laura, additional, Maestre Peiró, Ana, additional, Trujillo Santos, Javier, additional, Visonà, Adriana, additional, Fernández-Reyes, José Luis, additional, Monreal Bosch, Manuel, additional, Adarraga, M.D., additional, Agud, M., additional, Aibar, J., additional, Aibar, M.A., additional, Amado, C., additional, Arcelus, J.I., additional, Baeza, C., additional, Ballaz, A., additional, Barba, R., additional, Barbagelata, C., additional, Barrón, M., additional, Barrón-Andrés, B., additional, Bernal, M., additional, Blanco-Molina, A., additional, Botella, E., additional, Camon, A.M., additional, Cañas, I., additional, Casado, I., additional, Castro, J., additional, Chasco, L., additional, Criado, J., additional, de Ancos, C., additional, de Miguel, J., additional, del Toro, J., additional, Demelo-Rodríguez, P., additional, Díaz-Peromingo, J.A., additional, Di Campli, M.V., additional, Díez-Sierra, J., additional, Domínguez, I.M., additional, Encabo, M., additional, Escribano, J.C., additional, Falgá, C., additional, Farfán-Sedano, A.I., additional, Fernández de Roitegui, K., additional, Fernández-Capitán, C., additional, Fernández-Reyes, J.L., additional, Fidalgo, M.A., additional, Flores, K., additional, Font, C., additional, Font, L., additional, Francisco, I., additional, Furest, I., additional, Gabara, C., additional, Galeano-Valle, F., additional, García, M.A., additional, García-Bragado, F., additional, García de Herreros, M., additional, García-Hernáez, R., additional, García-Mullor, M.M., additional, García-Raso, A., additional, Gavín-Sebastián, O., additional, Gil-Díaz, A., additional, Gómez-Cuervo, C., additional, González-Martínez, J., additional, Grau, E., additional, Giménez-Suau, M., additional, Guirado, L., additional, Gutiérrez, J., additional, Hernández-Blasco, L., additional, Hernando, E., additional, Jara-Palomares, L., additional, Jaras, M.J., additional, Jiménez, D., additional, Joya, M.D., additional, Jou, I., additional, Lima, J., additional, Llamas, P., additional, Lobo, J.L., additional, López-Jiménez, L., additional, López-Miguel, P., additional, López-Núñez, J.J., additional, López-Reyes, R., additional, López-Sáez, J.B., additional, Lorenzo, A., additional, Loring, M., additional, Madridano, O., additional, Maestre, A., additional, Marchena, P.J., additional, Martín del Pozo, M., additional, Martín-Martos, F., additional, Mella, C., additional, Mellado, M., additional, Mercado, M.I., additional, Moisés, J., additional, Monreal, M., additional, Morales, M.V., additional, Muñoz-Blanco, A., additional, Muñoz-Guglielmetti, D., additional, Muñoz-Rivas, N., additional, Navas, M.S., additional, Nieto, J.A., additional, Núñez-Ares, A., additional, Núñez-Fernández, M.J., additional, Obispo, B., additional, Olid, M., additional, Olivares, M.C., additional, Orcastegui, J.L., additional, Ortega-Recio, M.D., additional, Osorio, J., additional, Otalora, S., additional, Otero, R., additional, Parra, P., additional, Parra, V., additional, Pedrajas, J.M., additional, Peinado, A., additional, Pellejero, G., additional, Pérez-Jacoiste, A., additional, Porras, J.A., additional, Portillo, J., additional, Riera-Mestre, A., additional, Rivas, A., additional, Rivera, F., additional, Rodríguez-Chiaradía, D.A., additional, Rodríguez-Cobo, A., additional, Rodríguez-Matute, C., additional, Rogado, J., additional, Rojo, R., additional, Rosa, V., additional, Ruiz-Artacho, P., additional, Ruiz-Giménez, N., additional, Ruiz-Ruiz, J., additional, Ruiz-Sada, P., additional, Sahuquillo, J.C., additional, Salgueiro, G., additional, Sampériz, A., additional, Sánchez-Martínez, R., additional, Sánchez-Muñoz-Torrero, J.F., additional, Sancho, T., additional, Soler, S., additional, Suriñach, J.M., additional, Tirado, R., additional, Torres, M.I., additional, Tolosa, C., additional, Trujillo-Santos, J., additional, Uresandi, F., additional, Valero, B., additional, Valle, R., additional, Vela, J.R., additional, Vidal, G., additional, Villares, P., additional, Zamora, C., additional, Gutiérrez, P., additional, Vázquez, F.J., additional, Engelen, M., additional, Vanassche, T., additional, Vehamme, P., additional, Hirmerova, J., additional, Malý, R., additional, Ait Abdallah, N., additional, Bertoletti, L., additional, Bura-Riviere, A., additional, Crichi, B., additional, Debourdeau, P., additional, Espitia, O., additional, Farge-Bancel, D., additional, Helfer, H., additional, Mahé, I., additional, Moustafa, F., additional, Poenou, G., additional, Schellong, S., additional, Braester, A., additional, Brenner, B., additional, Tzoran, I., additional, Bilora, F., additional, Brandolin, B., additional, Bucherini, E., additional, Ciammaichella, M., additional, Colaizzo, D., additional, Di Micco, P., additional, Grandone, E., additional, Imbalzano, E., additional, Maida, R., additional, Mastroiacovo, D., additional, Pace, F., additional, Pesavento, R., additional, Prandoni, P., additional, Quintavalla, R., additional, Rocci, A., additional, Siniscalchi, C., additional, Tufano, A., additional, Visonà, A., additional, Zalunardo, B., additional, Skride, A., additional, Strautmane, S., additional, Zaicenko, A., additional, Ferreira, M., additional, Fonseca, S., additional, Martins, F., additional, Meireles, J., additional, Bosevski, M., additional, Bounameaux, H., additional, Mazzolai, L., additional, Caprini, J.A., additional, Tafur, A.J., additional, Weinberg, I., additional, Wilkins, H., additional, and Bui, H.M., additional

Published
2020
Full Text
View/download PDF

30. 153P The Systemic Inflammation Response Index (SIRI) is a prognostic factor that correlates with tumor burden in advanced pancreatic cancer

Author

Pacheco-Barcia, V.E., primary, France, T., additional, Asselah, J., additional, Mondejar, R., additional, Zogopoulos, G., additional, Serrano, R., additional, Donnay, O., additional, Rogado, J., additional, Del Campo, L., additional, Martinez, E., additional, Martin, E., additional, Arlanzon, C., additional, Ochoa, P., additional, Guo, K., additional, Barrena, G., additional, and Colomer Bosch, R., additional

Published
2020
Full Text
View/download PDF

33. LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)

Author

Baena Espinar, J., primary, Torri, V., additional, Whisenant, J., additional, Hirsch, F.R., additional, Rogado, J., additional, de Castro Carpeño, J., additional, Halmos, B., additional, Ceresoli, G.L., additional, Rueda, A. Gomez, additional, Tiseo, M., additional, Felip, E., additional, Tarruella, M. Majem, additional, Monnet, I., additional, Tapan, U., additional, Wakelee, H., additional, Huang, L-C., additional, Garassino, M.C., additional, Peters, S., additional, Horn, L., additional, and Hellmann, M., additional

Published
2020
Full Text
View/download PDF

36. Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients

Author

Rogado, J., primary, Laorden, N Romero, additional, Torres, J M Sanchez, additional, Ramos-Levi, A., additional, Pacheco-Barcia, V.E., additional, Garcia, A I Ballesteros, additional, Arranz, R., additional, Lorenzo, A., additional, Gullon, P., additional, Garrido, A., additional, Serra, J.M., additional, Donnay, O., additional, Adrados, M., additional, Costas, P., additional, Aspa, J., additional, Alfranca, A., additional, Mondejar, R., additional, and Bosch, R Colomer, additional

Published
2019
Full Text
View/download PDF

38. Safety and outcomes of self-expandable metal stents (SEMS) versus emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab (BV)

Author

Pacheco-Barcia, V.E., primary, Mondéjar Solís, R., additional, Martínez-Sáez, O., additional, Longo, F., additional, Bermejo, E., additional, Moreno, J.A., additional, Marin, C., additional, Correa, A., additional, Maqueda, R., additional, Rogado, J., additional, García de Paredes, A., additional, Rodriguez de Santiago, E., additional, Pachón Olmos, V., additional, Ferreiro Monteagudo, R., additional, Rodriguez Garrote, M., additional, Carrato Mena, A., additional, Donnay, O., additional, Martin Perez, E., additional, Santander, C., additional, and Colomer Bosch, R., additional

Published
2018
Full Text
View/download PDF

40. Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab

Author

Pacheco-Barcia, V., primary, Solís, R. Mondéjar, additional, Saez, O. Martínez, additional, Muñoz, F. Longo, additional, Bermejo, E., additional, Monteagudo, J. Moreno, additional, Marin, C., additional, Correa, A., additional, Maqueda, R., additional, Rogado, J., additional, de Paredes, A. Garcia, additional, de Santiago, E. Rodriguez, additional, Olmos, V. Pachón, additional, Monteagudo, R. Ferreiro, additional, Garrote, M. Rodriguez, additional, Carrato, A., additional, Donnay, O., additional, Martin, E., additional, Santander, C., additional, and Colomer, R., additional

Published
2018
Full Text
View/download PDF

45. Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA+P)

Author

Lozano Mejorada, R., primary, Romero Laorden, N., additional, Jayaram, A., additional, López, F., additional, Sáez, M.I., additional, Villatoro, R., additional, Montesa, A., additional, Moreno, I., additional, Ruiz Vico, M., additional, García Ferrón, M., additional, Rogado, J., additional, Cendón Flórez, Y., additional, Nombela Blanco, P., additional, Rivera, L., additional, Grau, G., additional, Cruz Hernandez, J.J., additional, Lorente Estelles, D., additional, Attard, G., additional, Castro Marcos, E., additional, and Olmos Hidalgo, D., additional

Published
2017
Full Text
View/download PDF

46. Ischemic stroke as cancer predecessor and associated predictors

Author

Rogado, J., primary, Pacheco, V., additional, Mondejar, R., additional, Quintas, S., additional, Gullón, P., additional, Dotor, J., additional, Fenor de la Maza, M.D., additional, Obispo, B., additional, Reig-Roselló, G., additional, Pascual, T., additional, Ballesteros Garcia, A.I., additional, Donnay, O., additional, Sánchez-Torres, J.M., additional, López Ruiz, R., additional, Vivancos, J., additional, and Colomer Bosch, R., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results